UCB's CIMZIA Receives FDA Breakthrough Therapy Designation In Pregnant Women With APS

UCB's CIMZIA (certolizumab pegol) received FDA Breakthrough Therapy Designation for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with lupus-positive antiphospholipid syndrome. The designation can accelerate development and regulatory review for this potential new indication, strengthening CIMZIA's clinical and commercial outlook.